Table 1

AMD3100 reduced the levels of SDF-1, pro-MMP-1, MMP-13, and IL-1 in guinea pig synovial fluid and of IL-1 in guinea pig serum

SDF-1, ng/ml

Pro-MMP-1, ng/ml

MMP-13, ng/ml

IL-1, ng/ml

IL-1 (serum), pg/ml


AMD3100

0.209 ± 0.023a

2.350 ± 1.101a

7.620 ± 0.399a

1.108 ± 0.416a

71.946 ± 40.491a

Primary OA

0.340 ± 0.071

4.286 ± 1.173

8.771 ± 0.830

2.005 ± 0.521

137.857 ± 42.998

PBS

0.355 ± 0.079

4.459 ± 1.764

8.382 ± 1.041

1.782 ± 0.602

156.071 ± 35.557


Data are expressed as mean ± SD. AMD3100 (n = 13); primary OA, n = 11; PBS, n = 11. aP <0.05. The concentration of SDF-1, pro-MMP-1, and MMP-13 in the AMD3100-treated group was significantly lower than those of the primary OA group and the sham group. The high concentration of IL-1in synovial fluid and in serum was found in the primary OA and the PBS-treated groups, whereas blocking SDF-1/CXCR4 by AMD3100 significantly decreased the level of IL-1 in the AMD3100-treated animals.

Wei et al. Arthritis Research & Therapy 2012 14:R177   doi:10.1186/ar3930

Open Data